In a nutshell The authors investigated the safety and effectiveness of epcoritamab (DuoBody-CD3xCD20) for the treatment of patients with relapsed or refractory (r/r) CD20+ B-cell non-Hodgkin lymphoma (B-NHL). The study showed that this medication has promising effectiveness and safety in these patients. Some background B-NHL is a type of...Read More
Non-Hodgkin lymphoma Posts on Medivizor
In a nutshell The study aimed to investigate if very low-dose radiotherapy (VLDRT) was effective in treating patients with indolent (painless) non-Hodgkin lymphoma (NHL). This study concluded that this treatment can be effective in these patients. Some background Radiotherapy (RT) is an important treatment in managing patients...Read More
In a nutshell This study aimed to investigate the risk of infections in patients with blood cancers who were treated with new biological drugs. This study concluded that a high proportion of these patients experienced severe infections. However, the infection risk was similar to that of chemotherapy. Some background Treatments for...Read More
Investigating the side effect profiles of different PD-L1/PD-1 inhibitor-based combination therapies.
In a nutshell This study investigated the side effect profiles of different PD-1/PD-L1 inhibitor-based combination therapies. The data showed that PD-1/PD-L1 inhibitors in combination with chemotherapy were associated with a higher risk of treatment-related side effects than with targeted therapy or immunotherapy combinations. Some background...Read More
In a nutshell This review looked at options to preserve future fertility for young people diagnosed with blood cancer. Some background For teens and young adults, blood and bone marrow cancers are one of the most common types of cancer. These include Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), and acute leukemia. Fortunately, blood...Read More
Which type of CAR T cell therapy is best for patients with relapsed or refractory large B cell lymphoma?
In a nutshell The authors compared the safety and effectiveness of lisocabtagene maraleucel (liso-cel; Breyanzi) and axicabtagene ciloleucel (axi-cel; Yescarta) in patients with relapsed or refractory (r/r) large B cell lymphoma (LBCL). The study found that both treatments were similarly effective but liso-cel was better tolerated in these...Read More
In a nutshell The review aimed to assess chemotherapy-free treatment of follicular lymphoma (FL) and marginal zone lymphoma (MZL). Some background Standard therapy for slow-growing non-Hodgkin lymphoma (NHL) such as FL and MZL involves immunochemotherapy (ICT). ICT combines immunotherapy and chemotherapy treatments. However, many patients...Read More
Evaluating long-term safety and effectiveness of CT-P10 for the treatment of advanced follicular lymphoma
In a nutshell This study aims to investigate the long-term effectiveness and safety of the rituximab biosimilar CT-P10 (Truxima) in combination with cyclophosphamide (Cytoxan), vincristine (Oncovin), and prednisone (Deltasone) (CVP) compared with rituximab (Rituxan) for the treatment of advanced-stage follicular lymphoma (FL). The...Read More
In a nutshell This study aimed to review the safety and effectiveness of three chimeric antigen receptor (CAR) T cell therapies, axicabtagene ciloleucel (AXI; Yescarta), tisagenlecleucel (TIS; Kymriah), and lisocabtagene maraleucel (LIS; Breyanzi), for the treatment of blood cancers. This study concluded that AXI and TIS showed very good...Read More
In a nutshell This study looked at the use of two types of stem cell transplant (SCT) in the treatment of T-cell lymphoma. It found that both haploidentical and umbilical cord blood SCT were good options for these patients. Some background T-cell lymphoma is a cancer affecting a certain type of blood cell called T-cells. T-cells are...Read More
In a nutshell This study investigated the role of PET/CT scanning in the treatment of patients with recurrent or hard-to-treat B-cell non-Hodgkin’s lymphoma (NHL) after T-cell therapy. This study found that PET/CT scanning helped predict the effectiveness and side effects of treatment for these patients. Some background Chemoimmunotherapy...Read More
In a nutshell This study looked at the use and response of the Pfizer BioNTech COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma (NHL). It found that patients with NHL undergoing treatment with rituximab (Rituxan)/obinutuzumab (Gazyva) had a poorer immune response to this vaccine, compared to patients without...Read More